



**Tyrosine kinase epidermal cancer imaging:** Mishani and Hagooly focus on strategies for molecular imaging and quantification of epidermal growth factor receptor-tyrosine kinase in cancer and outline the potential for these techniques in clinical practice. . . . . **Page 1199**




**Significance of kinetic enhancement:** Berridge provides perspective on the role of kinetic enhancement in radiopharmaceutical effectiveness and previews an article in this issue of *JNM* on the effect of radiopharmaceutical-to-serum protein binding on tracer kinetics. . . . **Page 1203**

**Preoperative PET in head and neck cancer:** Rodrigues and colleagues compare optimized whole-body and dedicated high-resolution contrast-enhanced PET/CT protocols and contrast-enhanced CT in preoperative staging of primary squamous cell carcinoma of the head and neck. . . . . **Page 1205**




**PET detection of bone metastases:** Putzer and colleagues assess the comparative diagnostic values of CT imaging and somatostatin analog <sup>68</sup>Ga-DOTATOC PET in early detection of bone metastases from neuroendocrine tumors. . . . **Page 1214**



**<sup>11</sup>C-acetate uptake regulation in HCC:** Yun and colleagues explore patterns of <sup>11</sup>C-acetate and <sup>18</sup>F-FDG uptake on PET/CT and expression of regulatory enzymes related to glycolysis and lipid synthesis in hepatocellular carcinoma. . . . **Page 1222**

**Receptor mapping with Hypotime:** Møller and colleagues describe a method of calculation that uses <sup>11</sup>C-WAY washout rather than accumulation on PET to map serotonin 5HT<sub>1A</sub> receptors in the human brain. . . . . **Page 1229**




**<sup>123</sup>I-MIBG and <sup>18</sup>F-FDG in neuroblastoma:** Sharp and colleagues assess differences in diagnostic utility of <sup>123</sup>I-MIBG scintigraphy and <sup>18</sup>F-FDG PET in patients with stages 1–4 neuroblastoma. . . . . **Page 1237**

**Parkin gene mutations and dopamine:** Ribeiro and colleagues use <sup>18</sup>F-fluoro-L-DOPA, <sup>11</sup>C-PE2I, and <sup>11</sup>C-raclopride PET to characterize patterns of dopaminergic lesions and related clinical manifestations in young-onset Parkinson disease patients with and without mutations of the Parkin gene. . . . . **Page 1244**


**<sup>18</sup>F-Flutemetamol PET:** Nelissen and colleagues report on a phase 1 study of <sup>18</sup>F-flutemetamol, a thioflavin derivative of

Pittsburgh compound B, including brain kinetic modeling, image acquisition optimization, and comparison of brain retention in Alzheimer disease patients and healthy controls. . . . . **Page 1251**



**Altered serotonin transporters in AD:** Ouchi and colleagues examine the relationship of clinical depression in early-to-moderate Alzheimer disease to changes in the brain serotonergic system and glucose metabolism as assessed by <sup>11</sup>C-DASB and <sup>18</sup>F-FDG PET. . . . . **Page 1260**

**P-gp activity at the human BBB:** Muzi and colleagues expand on previous studies designed to use <sup>11</sup>C-verapamil PET to image cyclosporine inhibition of multiple-drug resistance transporter P-glycoprotein activity at the blood-brain barrier in healthy humans. . . . . **Page 1267**




**Novel translocator protein tracer:** Endres and colleagues describe initial PET studies in humans with <sup>11</sup>C-DPA-713, a radioligand that binds to translocator proteins with high affinity, and discuss potential applications in assessment of neuroinflammation. . . . . **Page 1276**

**<sup>11</sup>C-Methionine PET in MI:** Morooka and colleagues examine whether <sup>11</sup>C-methionine localizes in areas of myocardial infarction after successful reperfusion and assess the

potential for PET imaging of the initial processes of remodeling. . . . . **Page 1283**

**Single-shot cardiorenal scintigraphy:**

Fommei and colleagues explore the hypothesis that a single combined cardiorenal <sup>99m</sup>Tc-tetrofosmin scintigraphy study can allow simultaneous investigation of cardiac and renal pathology in cardiovascular patients. . . . . **Page 1288**



**Predictive CAD testing:** Shaw and Narula provide an educational overview of risk assessment, predictive accuracy, and economic outcomes for 3 commonly applied cardiac imaging procedures and highlight the potential added value of hybrid imaging. . . . . **Page 1296**

**Measuring spatial resolution in PET:**

Lodge and colleagues report on a quality assurance method for measuring spatial resolution in PET, designed to assist in standardization of data collection for enhanced comparison of results, particularly those from multicenter trials. . . . **Page 1307**

**TOF PET tumor detectability:**

Kadrmaz and colleagues evaluate the effect of time-of-flight technology on observer performance in detecting and localizing focal warm lesions in noisy PET images acquired in an anthropomorphic phantom. . . . . **Page 1315**

**Kinetic model for CSF RIT delivery:**

Lv and colleagues describe a pharmacokinetic


model to evaluate the role of kinetic and transport parameters of radioimmunotherapy designed to treat leptomeningeal metastases using antibodies administered directly into the cerebrospinal fluid. . . . . **Page 1324**

**MDR1 influences <sup>64</sup>Cu-ATSM retention:**

Liu and colleagues investigate the role of multidrug resistance type 1 protein expression in accumulation and retention of two <sup>64</sup>C-labeled tracers and discuss the implications for imaging of tumor hypoxia. . . . . **Page 1332**

**SPECT/CT and HER2 expression:**

McLarty and colleagues describe animal studies on <sup>111</sup>In-DTPA-pertuzumab SPECT detection of early molecular response to trastuzumab as indicated by HER2 downregulation and of tumor response with decreased numbers of HER2-positive viable tumor cells. . . . . **Page 1340**




**Central nAChR tracer:** Valette and colleagues report on in vitro characterization and in vivo primate studies of a novel radioligand for PET imaging of central nicotinic acetylcholine receptors. . . . . **Page 1349**

**Quantitative imaging of angiogenesis:**

Dobrucki and colleagues report on validation studies of a semiautomated approach for serial quantitative evaluation

of peripheral angiogenesis with micro-SPECT/CT. . . . . **Page 1356**



**K-Ras and uptake in thyroid cancer:**


Prante and colleagues explore molecular mechanisms behind increases in <sup>18</sup>F-FDG uptake on PET imaging in dedifferentiated thyroid cancer, with findings that point to oncogene activation of intracellular signal transduction cascades. . . . . **Page 1364**

**Apoptosis in right ventricular disease:**

Campian and colleagues study the role of apoptosis in this setting by monitoring disease progression and treatment response with <sup>99m</sup>Tc-annexin-V scintigraphy in rats. . . . . **Page 1371**

**Serum protein binding of <sup>123</sup>I-IMP:**

Kuga and colleagues investigate whether amino acid infusion can improve cerebral accumulation of this SPECT tracer by competitive displacement of serum protein binding. . . . . **Page 1378**



**ON THE COVER**

Time-of-flight PET significantly improves observer performance in detecting focal lesions on a noisy background, as illustrated by this <sup>18</sup>F-FDG PET/CT scan of a patient with esophageal cancer and a body mass index of 27. The reconstructions that include time-of-flight information show improved uniformity in the liver and mediastinal region and better delineate the bone marrow in the ribs and spine.

See page 1322.

